Uttarakhand eateries on Kanwar Yatra route must display food licenses
Owners of hotels, dhabas, food carts and stalls along the pilgrimage route will have to display a clean copy of their license or registration certificate prominently so that consumers can easily see it, Health Secretary and Commissioner Food Safety and Drug Administration R Rajesh Kumar said.
Dehradun, Jul 2 (PTI) The Uttarakhand government has made it mandatory for eateries on the Kanwar Yatra route to prominently display their food licenses or registration certificates.
'Food Safety Display Board' should also be installed in hotels, eateries, dhabas and restaurants at a clearly visible place, so that the customer can know who is responsible for the quality of food.
Action will be taken against businessmen who do not follow these instructions under Section 55 of the Food Safety Act 2006, under which a fine of up to Rs 2 lakh can be imposed on those violating the order, Kumar said.
All officials concerned should ensure that these orders are strictly followed, he said.
There will be no compromise with the quality of food served to devotees at pandals and community kitchens, he said.
'Immediate legal action will be taken against adulterators and those who tamper with the standards. The health of the pilgrims is our top priority,' he added.
Special teams of food safety officers have been deployed in Haridwar, Dehradun, Tehri, Pauri and Uttarkashi districts who will regularly collect samples of milk, sweets, oil, spices and beverages, etc. from the pandals and send them to laboratories for testing. If any sample does not meet the standards, the concerned place will be closed immediately, Additional Commissioner Food Safety and Drug Administration Tajbar Singh Jaggi said. PTI ALM DIV DIV
This report is auto-generated from PTI news service. ThePrint holds no responsibility for its content.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New Indian Express
an hour ago
- New Indian Express
Telangana to emerge as premier health tourism hub: CM Revanth Reddy
HYDERABAD: Chief Minister A Revanth Reddy on Wednesday said Telangana is fast becoming a leading healthcare hub in India, thanks to premier hospitals and advanced medical infrastructure. Inaugurating the new 300-bed multispecialty branch of AIG Hospitals at Banjara Hills, he said the government is committed to promoting health tourism and accessible healthcare. The chief minister said health tourism will be a key focus in the upcoming Telangana Rising 2047 policy. Health and education remain top government priorities, with Rs 11,500 crore allocated to health and Rs 21,500 crore to education in this fiscal year, he added. Currently, the state provides free medical care of up to Rs 10 lakh for the poor. To boost preventive healthcare, health profile cards with unique IDs will be issued to women in self-help groups, Revanth said, adding that top experts like Dr Nori Dattatreya have been empanelled to strengthen healthcare delivery. Docs urged to serve in govt hosps for at least a month The chief minister highlighted Hyderabad's strong air connectivity with Middle Eastern nations, making it a top destination for medical tourists. He urged doctors to serve in government hospitals for at least one month as social responsibility and called on public hospitals to match private sector standards.
Business Standard
an hour ago
- Business Standard
Biocon's biologics arm gets regulatory approval in EU for Denosumab biosimilars
Biocon said that Biocon Biologics has received the European Commission (EC) marketing authorisation in the European Union (EU) for Vevzuo and Evfraxy biosimilars of Denosumab. Denosumab is a human monoclonal antibody that targets and binds a protein known as RANKL (Receptor Activator of Nuclear Factor Kappa-B Ligand). RANKL plays a crucial role in the formation, function, and survival of osteoclasts, which are the cells responsible for bone resorption. By blocking RANKL, denosumab effectively inhibits the breakdown of bone, leading to increased bone mass and strength. Vevzuo is authorised for the prevention of bone complications in adults with advanced cancer involving bone and the treatment of adults and skeletally mature adolescents with giant cell tumour (GCT) of bone. Evfraxy is authorised for the treatment of osteoporosis in men and postmenopausal women, the treatment of bone loss linked to hormone ablation in men with prostate cancer at increased risk of fractures or treatment of bone loss associated with long-term systemic glucocorticoid therapy in adults. Clinical data showed that both Denosumab biosimilars have comparable quality, safety, and efficacy to the reference product. The marketing authorisation follows a positive opinion issued by the European Medicines Agencys Committee for Medicinal Products for Human Use (CHMP) on April 25, 2025. Shreehas Tambe, CEO & managing director, Biocon Biologics, said: The approval of Vevzuo and Evfraxy in Europe underscores our strong scientific expertise and commitment to expanding patient access to essential medicines, including to new therapeutic areas such as bone health. In the past 18 months, we have successfully secured regulatory approvals for three biosimilars in Europe and two in the UK. These Denosumab biosimilars mark another significant milestone in our rapid expansion, and support for healthcare systems in the region. Biocon is a global biopharma company dedicated to improving affordable access to therapies for chronic conditions like diabetes, cancer, and autoimmune diseases. The companys consolidated net profit surged 154.2% to Rs 344.50 crore on a 12.8% jump in net sales to Rs 4,358.10 crore in Q4 FY25 over Q4 FY24. The scrip shed 0.20% to currently trade at Rs 367.65 on the BSE.
Hindustan Times
2 hours ago
- Hindustan Times
Kiran Mazumdar-Shaw hits back at Karnataka CM Siddaramaiah for hinting COVID vaccines are behind heart attacks in Hassan
Biocon Executive Chairperson Kiran Mazumdar-Shaw has strongly criticized Karnataka Chief Minister Siddaramaiah for suggesting that COVID-19 vaccines may be linked to a recent spike in heart attack-related deaths in Hassan district. Her comments came in response to a social media post by the Chief Minister, in which he appeared to raise questions about the safety of the vaccines. Biotechnology pioneer Kiran Mazumdar-Shaw(PTI File Photo) In his post, Siddaramaiah revealed that over 20 individuals in Hassan district had died of heart attacks in the past month alone. While assuring the public that the government was treating the situation with utmost seriousness, he also raised the possibility that COVID-19 vaccinations might have contributed to these fatalities. READ | Four heart attack deaths in a day spark alarm in Hassan: Karnataka CM Siddaramaiah orders expert probe 'Orders were given to this same committee back in February to conduct a thorough study on the reasons behind sudden deaths among young people in the state, and whether the COVID vaccines could have any adverse effects,' Siddaramaiah wrote. 'It cannot be denied that the hasty approval and distribution of the Covid vaccine to the public could also be a reason for these deaths, as several studies worldwide have recently indicated that COVID vaccines could be a cause for the increasing number of heart attacks,' he added. READ | Karnataka orders probe as heart attacks rise in Hassan, 18 within a month Reacting to these remarks, Kiran Mazumdar-Shaw issued a pointed rebuttal. 'COVID-19 vaccines developed in India were approved under the Emergency Use Authorisation framework, following rigorous protocols aligned with global standards for safety and efficacy. To suggest that these vaccines were 'hastily' approved is factually incorrect and contributes to public misinformation," she replied. 'These vaccines have saved millions of lives and, like all vaccines, may cause side effects in a very small number of individuals. It is important to acknowledge the science and data-driven processes behind their development, rather than engage in retrospective blame,' she further wrote. READ | Govt orders probe into Hassan cardiac deaths, vaccine link under lens The expert committee's findings are expected within the next ten days.
